Copenhagen-based Lundbeck Inc. recently suffered a setback in its Phase III DAYBREAK trial of Lu AF35700 for treatment-resistant schizophrenia.
The novel antipsychotic didn’t show statistical superiority versus conventional therapy on the primary endpoint (change in Total PANSS from randomization...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
